or Try an Advanced Search...

    Technical Analysis for EDIT - Editas Medicine, Inc.

    Grade Last Price % Change Price Change
    F 4.61 -1.28% -0.06
    EDIT closed down 1.28 percent on Monday, July 1, 2024, on 78 percent of normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    8 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical EDIT trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish 0.00%
    New 52 Week Low Weakness 0.00%
    Outside Day Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Down 5 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    New 52 Week Closing Low Bearish -1.28%
    New 52 Week Low Weakness -1.28%
    Down 3 Days in a Row Weakness -1.28%
    Older End-of-Day Signals for EDIT ...

       Recent Intraday Alerts

    Alert Time
    Down 2 % about 6 hours ago
    Outside Day about 6 hours ago
    Fell Below Previous Day's Low about 6 hours ago
    New 52 Week Low about 6 hours ago
    Down 1% about 8 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    EDIT Chart by TradingView
    Basic chart:

    Profile

    As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biology Immune System Genetics Enzymes Genetic Engineering Genome DNA CRISPR Genome Editing Cas9

    Is EDIT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 30 Is Editas Medicine, Inc. (EDIT) One of the Best Biotech Penny Stocks to Buy Now?
    Jun 27 What Makes Editas Medicine, Inc. (EDIT) One of the Best Small-Cap Stocks with Highest Upside Potential?
    Jun 25 3 Gene Editing Stocks That Could Make Your Grandchildren Rich
    Jun 17 Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies
    Jun 14 Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
    Jun 14 Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
    Jun 7 Editas (EDIT) Down 2.3% Since Last Earnings Report: Can It Rebound?
    May 22 EVP, Chief Financial Officer Erick Lucera Sells 22,337 Shares of Editas Medicine Inc (EDIT)
    May 16 Editas Medicine, Inc. (EDIT) RBC Capital Markets Global Healthcare Conference (Transcript)
    May 15 Editas Medicine: Promising Milestone Achieved But Be Patient
    See more EDIT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 11.69
    52 Week Low 4.57
    Average Volume 2,228,845
    200-Day Moving Average 7.56
    50-Day Moving Average 5.38
    20-Day Moving Average 5.20
    10-Day Moving Average 4.91
    Average True Range 0.33
    RSI (14) 35.06
    ADX 8.58
    +DI 24.12
    -DI 27.14
    Chandelier Exit (Long, 3 ATRs) 5.22
    Chandelier Exit (Short, 3 ATRs) 5.57
    Upper Bollinger Bands 5.92
    Lower Bollinger Band 4.48
    Percent B (%b) 0.09
    BandWidth 27.65
    MACD Line -0.24
    MACD Signal Line -0.19
    MACD Histogram -0.0508
    Fundamentals Value
    Market Cap 376.52 Million
    Num Shares 81.7 Million
    EPS -2.69
    Price-to-Earnings (P/E) Ratio -1.71
    Price-to-Sales 25.99
    Price-to-Book 1.69
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 5.05
    Resistance 3 (R3) 5.08 4.97 4.97
    Resistance 2 (R2) 4.97 4.86 4.95 4.95
    Resistance 1 (R1) 4.79 4.79 4.74 4.76 4.92
    Pivot Point 4.68 4.68 4.65 4.66 4.68
    Support 1 (S1) 4.50 4.57 4.45 4.47 4.30
    Support 2 (S2) 4.39 4.50 4.37 4.27
    Support 3 (S3) 4.21 4.39 4.25
    Support 4 (S4) 4.18